SE0202365D0 - New formulation and use thereof - Google Patents

New formulation and use thereof

Info

Publication number
SE0202365D0
SE0202365D0 SE0202365A SE0202365A SE0202365D0 SE 0202365 D0 SE0202365 D0 SE 0202365D0 SE 0202365 A SE0202365 A SE 0202365A SE 0202365 A SE0202365 A SE 0202365A SE 0202365 D0 SE0202365 D0 SE 0202365D0
Authority
SE
Sweden
Prior art keywords
new formulation
composition
sexual
dysfunction
compound
Prior art date
Application number
SE0202365A
Other languages
English (en)
Swedish (sv)
Inventor
Nils-Olof Lindberg
Katarina Lindell
Kristina Thyresson
Alice C Martino
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0202365A priority Critical patent/SE0202365D0/xx
Publication of SE0202365D0 publication Critical patent/SE0202365D0/xx
Priority to BR0313224-2A priority patent/BR0313224A/pt
Priority to RU2005102835/15A priority patent/RU2312665C2/ru
Priority to CA002495527A priority patent/CA2495527C/en
Priority to AU2003239038A priority patent/AU2003239038B2/en
Priority to MXPA05000978A priority patent/MXPA05000978A/es
Priority to NZ537520A priority patent/NZ537520A/en
Priority to EP03733755A priority patent/EP1539096A1/en
Priority to JP2004525901A priority patent/JP2005539008A/ja
Priority to PCT/SE2003/001022 priority patent/WO2004012702A1/en
Priority to CN038188910A priority patent/CN1674866B/zh
Priority to TW092120418A priority patent/TW200418470A/zh
Priority to US10/634,159 priority patent/US20040126448A1/en
Priority to AR20030102814A priority patent/AR040797A1/es
Priority to IL16603104A priority patent/IL166031A0/xx
Priority to ZA2005/00051A priority patent/ZA200500051B/en
Priority to US11/561,650 priority patent/US20070092554A1/en
Priority to US12/623,723 priority patent/US20100069397A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0202365A 2002-08-05 2002-08-05 New formulation and use thereof SE0202365D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (sv) 2002-08-05 2002-08-05 New formulation and use thereof
RU2005102835/15A RU2312665C2 (ru) 2002-08-05 2003-06-18 Новые быстродействующие фармацевтические композиции, содержащие соединения, активные при сексуальной дисфункции, и порошок какао, и их применение
JP2004525901A JP2005539008A (ja) 2002-08-05 2003-06-18 カカオ粉末を含む性機能障害用化合物を含有し、作用発現が迅速な新規医薬製剤およびその使用
CN038188910A CN1674866B (zh) 2002-08-05 2003-06-18 含有治疗性功能障碍化合物和可可粉的药物制剂及其用途
CA002495527A CA2495527C (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
AU2003239038A AU2003239038B2 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
MXPA05000978A MXPA05000978A (es) 2002-08-05 2003-06-18 Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
NZ537520A NZ537520A (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
EP03733755A EP1539096A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
BR0313224-2A BR0313224A (pt) 2002-08-05 2003-06-18 Composição farmacêutica contendo composto para terapia da disfunção sexual para ser administrada de modo oral que proporciona rápido inìcio de seus efeitos farmacológicos
PCT/SE2003/001022 WO2004012702A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
TW092120418A TW200418470A (en) 2002-08-05 2003-07-25 New formulations and use thereof
AR20030102814A AR040797A1 (es) 2002-08-05 2003-08-05 Formulaciones para la disfuncion sexual y usos de las mismas
US10/634,159 US20040126448A1 (en) 2002-08-05 2003-08-05 Sexual dysfunction compounds
IL16603104A IL166031A0 (en) 2002-08-05 2004-12-28 New sexual-dysfunction-compound containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
ZA2005/00051A ZA200500051B (en) 2002-08-05 2005-01-04 New sexual-dysfuction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
US11/561,650 US20070092554A1 (en) 2002-08-05 2006-11-20 Sexual Dysfunction Compounds
US12/623,723 US20100069397A1 (en) 2002-08-05 2009-11-23 Sexual dysfunction compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (sv) 2002-08-05 2002-08-05 New formulation and use thereof

Publications (1)

Publication Number Publication Date
SE0202365D0 true SE0202365D0 (sv) 2002-08-05

Family

ID=20288677

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202365A SE0202365D0 (sv) 2002-08-05 2002-08-05 New formulation and use thereof

Country Status (15)

Country Link
EP (1) EP1539096A1 (xx)
JP (1) JP2005539008A (xx)
CN (1) CN1674866B (xx)
AR (1) AR040797A1 (xx)
AU (1) AU2003239038B2 (xx)
BR (1) BR0313224A (xx)
CA (1) CA2495527C (xx)
IL (1) IL166031A0 (xx)
MX (1) MXPA05000978A (xx)
NZ (1) NZ537520A (xx)
RU (1) RU2312665C2 (xx)
SE (1) SE0202365D0 (xx)
TW (1) TW200418470A (xx)
WO (1) WO2004012702A1 (xx)
ZA (1) ZA200500051B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
EP3299010B1 (de) 2016-09-21 2022-11-09 LTS Lohmann Therapie-Systeme AG Orale darreichungsform
BR112020017468A2 (pt) 2018-03-01 2020-12-22 Lts Lohmann Therapie-Systeme Ag Forma de dosagem oral com cacau livre de teobromina

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ES2105970B1 (es) * 1995-08-02 1998-07-01 S A L V A T Lab Sa Composicion farmaceutica oral de ciprofloxacino, no acuosa, estable y con caracteristicas organolepticas mejoradas.
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
ID21806A (id) * 1997-01-06 1999-07-29 Pfizer Bentuk penakaran farmasi yang secara cepat dilepaskan dan yang menutup rasa
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
JP2000095710A (ja) * 1998-09-21 2000-04-04 Taisho Pharmaceut Co Ltd カカオ末を配合した経口用固形製剤
JP2000119198A (ja) * 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
US6060094A (en) * 1998-10-30 2000-05-09 Nestec S.A. Method of reducing fat in fat-based coating for confectionery products
SE9803986D0 (sv) 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
JP2003506394A (ja) 1999-08-10 2003-02-18 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
BR0012822A (pt) 1999-12-30 2004-03-09 Tap Holdings Inc Formulação farmacêutica, e, forma de dosagem em tablete
AU2001273545A1 (en) 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Also Published As

Publication number Publication date
RU2005102835A (ru) 2005-08-10
CA2495527C (en) 2008-12-30
AU2003239038B2 (en) 2008-01-03
BR0313224A (pt) 2005-07-05
MXPA05000978A (es) 2005-12-12
JP2005539008A (ja) 2005-12-22
CN1674866A (zh) 2005-09-28
AR040797A1 (es) 2005-04-20
RU2312665C2 (ru) 2007-12-20
EP1539096A1 (en) 2005-06-15
AU2003239038A1 (en) 2004-02-23
IL166031A0 (en) 2006-01-15
ZA200500051B (en) 2006-12-27
WO2004012702A1 (en) 2004-02-12
NZ537520A (en) 2006-11-30
TW200418470A (en) 2004-10-01
CN1674866B (zh) 2012-09-26
CA2495527A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
TW200510375A (en) New compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
SI1478339T1 (sl) Farmacevtske formulacije antineoplastičnih sredstev, zlasti temozolomida, postopki za pripravo in uporabo le-teh
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
SE0103211D0 (sv) New formulations and use thereof
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
WO2003075857A3 (en) Amino-methyl substituted tetracycline compounds
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
SE0202539D0 (sv) Compounds
SE0100901D0 (sv) New composition
TW200505875A (en) Novel compounds
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
ATE445389T1 (de) Liposomale glucocorticoide
GB0426313D0 (en) Therapeutic agents
MXPA03010761A (es) Combinaciones farmaceuticas.
SG116507A1 (en) Pharmaceutical dosage form and method of making.
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
PT1404304E (pt) Comprimido contendo cetirizina e pseudoefedrina
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
SE0202365D0 (sv) New formulation and use thereof